Cytoplasmic localization of p63 is associated with poor patient survival in lung adenocarcinoma

Histopathology

Volumn 49, Issue 4, 2006, Pages 349-357

  Narahashi, T ^a   Niki, T ^a,b   Wang, T ^a   Goto, A ^a   Matsubara, D ^a   Funata, N ^c   Fukayama, M ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

Author keywords

Cytoplasm; Immunohistochemistry; Lung adenocarcinoma; p63; Prognosis

Indexed keywords

PROTEIN P63;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL TIME; UNIVARIATE ANALYSIS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; CELL NUCLEUS; CYTOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LUNG NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33748752117     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2006.02507.x     Document Type: Article

References (26)

1. Morita T. A statistical study of lung cancer in the annual of pathological autopsy cases in Japan, from 1958 to 1997, with reference to time trends of lung cancer in the world. Jpn J. Cancer Res. 2002; 93; 15-23.
2. Visbal AL, Williams BA, Nichols FC 3rd et al. Gender differences in non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002. Ann. Thorac. Surg. 2004; 78; 209-215.
3. Kurokawa T, Matsuno Y, Noguchi M, Mizuno S, Shimosato Y. Surgically curable "early" adenocarcinoma in the periphery of the lung. Am. J. Surg. Pathol. 1994; 18; 431-438.
4. Kawabuchi B, Moriyama S, Hironaka M et al. p16 inactivation in small sized lung adenocarcinoma: its association of poor prognosis. Int. J. Cancer 1999; 84; 49-53.
5. Goto A, Niki T, Moriyama S et al. Immunohistochemical study of Skp2 and Jab1, two key molecules in the degradation of P27, in lung adenocarcinoma. Pathol. Int. 2004; 54; 675-681.
6. Goto A, Niki T, Li C-P et al. Loss of TSLC1 expression in lung adenocarcinoma: relationships with histological subtypes, sex and prognostic significance. Cancer Sci. 2005; 96; 480-486.
7. Irwin MS, Kaelin WG. P53 family update: p73 and p63 develop their own identities. Cell Growth Different. 2001; 12; 337-349.
8. Di Como CJ, Urist MJ, Babayan I et al. p63 expression profiles in human normal and tumor tissues. Clin. Cancer Res. 2002; 8; 494-501.
9. Nylander K, Vojtesek B, Nenutil R et al. Differential expression of p63 isoforms in normal tissues and neoplastic cells. J. Pathol. 2002; 198; 417-427.
10. Hagiwara K, McMenamin MG, Miura K, Harris CC. Mutational analysis of the p63/p73L/p51/p40/CUSP/KET gene in human cancer cell lines using intronic primers. Cancer Res. 1999; 59; 4165-4169.
11. Massion PP, Taflan PM, Jamshedur Rahman SM et al. Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Res. 2003; 63; 7113-7121.
12. Pelosi G, Pasini F, Olsen Stenholm C et al. p63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas? J. Pathol. 2002; 198; 100-109.
13. Iwata T, Uramoto H, Sugio K et al. A lack of prognostic significance regarding DeltaNp63 immunoreactivity in lung cancer. Lung Cancer 2005; 50; 67-73.
14. Beer DG, Kardia SL, Huang CC et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat. Med. 2002; 8; 816-824.
15. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111; 1710-1717.
16. The Japanese Lung Cancer Society. General rule for clinical and pathological record of lung cancer. Tokyo: Kanehara and Co. 1999.
17. Au NH, Cheang M, Huntsman DG et al. Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers. J. Pathol. 2004; 204; 101-109.
18. Nishio M, Koshikawa T, Kuroishi T et al. Prognostic significance of abnormal p53 accumulation in primary, resected non-small-cell lung cancers. J. Clin. Oncol. 1996; 14; 497-502.
19. Niki T, Kohno T, Iba S et al. Frequent co-localization of Cox-2 and laminin-5 gamma2 chain at the invasive front of early-stage lung adenocarcinomas. Am. J. Pathol. 2002; 160; 1129-1141.
20. Wang BY, Gil J, Kaufman D et al. P63 in pulmonary epithelium, pulmonary squamous neoplasms, and other pulmonary tumors. Hum. Pathol. 2002; 33; 921-926.
21. Au NH, Gown AM, Cheang M et al. P63 expression in lung carcinoma: a tissue microarray study of 408 cases. Appl. Immunohistochem. Mol. Morph. 2004; 12; 240-247.
22. Ghioni P, D'Alessandra Y, Mansueto G et al. The protein stability and transcriptional activity of p63alpha are regulated by SUMO-1 conjugation. Cell Cycle 2005; 4; 183-190.
23. Nikolaev AY, Li M, Puskas N, Qin J, Gu W. Parc: a cytoplasmic anchor for p53. Cell 2003; 112; 29-40.
24. Maisse C, Guerrieri P, Melino G. p73 and p63 protein stability: the way to regulate function? Biochem. Pharmacol. 2003; 66; 1555-1561.
25. Patturajan M, Nomoto S, Sommer M et al. DeltaNp63 induces beta-catenin nuclear accumulation and signaling. Cancer Cell 2002; 1; 369-379.
26. Ratovitski EA, Patturajan M, Hibi K et al. p53 associates with and targets Delta Np63 into a protein degradation pathway. Proc. Natl Acad. Sci. USA 2001; 98; 1817-1822.